Acyclovir
- Generic Name
- Acyclovir
- Brand Names
- Sitavig, Xerese, Zovirax
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N5O3
- CAS Number
- 59277-89-3
- Unique Ingredient Identifier
- X4HES1O11F
- Background
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Acyclovir was granted FDA approval on 29 March 1982.
- Indication
An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients. An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older. An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis. An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.
- Associated Conditions
- Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2012-11-20
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01729767
- Locations
- 🇮🇷
Amiralam Hospital, Tehran, Iran, Islamic Republic of
Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- EMS
- Target Recruit Count
- 177
- Registration Number
- NCT01327144
- Locations
- 🇧🇷
Allergisa, Campinas, São Paulo, Brazil
🇧🇷Centro de Medicina Reprodutiva Dr Carlos Isaia Filho, Porto Alegre, RS, Brazil
🇧🇷Loema, Campinas, SP, Brazil
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- EMS
- Target Recruit Count
- 150
- Registration Number
- NCT01281007
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷Caep Centro Avancado de Estudos E Pesquisas Ltda, Campinas, SP, Brazil
🇧🇷Centro de Medicina Reprodutiva Dr Carlos Isaia Filho Ltda, Porto Alegre, RS, Brazil
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
- Conditions
- Herpes Labialis
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- EMS
- Target Recruit Count
- 76
- Registration Number
- NCT01257074
- Locations
- 🇧🇷
Flavia Addor, São Paulo, Brazil
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 32
- Registration Number
- NCT01026454
- Locations
- 🇰🇪
Thika Partners in Prevention, Thika, Kenya
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Phillip Brian Smith
- Target Recruit Count
- 32
- Registration Number
- NCT00942084
- Locations
- 🇺🇸
Tulane School of Medicine, New Orleans, Louisiana, United States
🇺🇸Wesely Medical Center, Wichita, Kansas, United States
🇺🇸Duke University, Durham, North Carolina, United States
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT00855309
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 88
- Registration Number
- NCT00808405
- Locations
- 🇿🇦
Reproductive Health and HIV Research Unit (RHRU), Johannesburg, South Africa
🇿🇲Center for Infectious Disease Research of Zambia (CIDRZ), Lusaka, Zambia
Phase 3 Clinical Study for the Treatment of Cold Sore
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 1727
- Registration Number
- NCT00769314
- Locations
- 🇵🇱
Naukowo-Badawczy i Naukowo-Dydaktyczny Ośrodek Dermatologii Estetycznej, Dermatochirurgii i Fotodermatologii, Gdynia, Poland
🇵🇱Gabinet Internistyczny, Warszawa, Poland
🇵🇱NZOZ Atopia, Al. J., Kraków, Poland
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
- Conditions
- Herpes Labialis
- Interventions
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2008-08-15
- Lead Sponsor
- Medivir
- Target Recruit Count
- 201
- Registration Number
- NCT00735761
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.